Relief matters most S K I H i FROM EASE THE ITCH OF ECZEMA ----------------------------- calcineurin inhibitors, including Protopic, in any age group should be avoided and application limited to areas of involvement with atopic dermatitis. The diagnosis of atopic dermatitis should be confirmed if signs and symptoms do not improve within 6 weeks. Protopic is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment The most common adverse events associated with the use of Protopic included the sensation of skin burning, pruritus, flu-like symptoms, and headache. The use of Protopic should be avoided on known or suspected malignant lesions. The use of Protopic on patients with Netherton's syndrome or similar skin diseases is not recommended. Patients should minimize or avoid natural or artificial sunlight exposure. Skin infections should be cleared prior to application, and there may be an increased risk of certain skin infections. Protopic should not be used with occlusive dressings. Disrupt the itch-scratch cycle. When other remedies haven't worked. Protopic (tacrolimus) Ointment may be effective treatment for patients with moderate to severe atopic dermatitis. Patients reported 5 times greater reduction in itch after treatment with Protopic compared to vehicle.1Find out more at www.protopic.com. important Safety Information Protopic Ointment, both 0.03%and 0.1% for adults and only 0.03% for children aged 2 to 15years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis or when those treatments are not advisable. Protopic is not indicated for children younger than 2 years of age. WARNING: long-term safety of topical calcineurin inhibitors has not been established (beyond 1 year of non-continuous use). Although a causal relationship has not been established, rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including Protopic. Therefore, continuous long-term use of topical Please see the next page for a brief summary of the ful PrescribingInformatkxv References. 1 Hdrifm Am Acad Dermatol 200T;44^28-S38. ©2007 AstetasPhamaUSyInc PRT24929A 2/07 Printed *>U$A . fl*
RkJQdWJsaXNoZXIy NDMwNDAx